Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec and Elan give Tysabri update

Biogen Idec and Elan give Tysabri update

7th January 2008

Biogen Idec and Elan have announced new information regarding the use, safety and exposure worldwide of Tysabri (natalizumab) in patients with multiple sclerosis.

The companies report that over 21,000 patients are undergoing commercial or clinical therapy with the drug worldwide, with safety data continuing to back a good benefit-risk profile for the compound.

Around 2,500 physicians have prescribed Tysabri in the US, with 12,900 patients receiving the drug commercially nationwide.

In the rest of the world, around 7,500 patients are on Tysabri commercially, while 700 patients are being administered with the drug in global clinical trials.

The compound is approved in the EU for the treatment of relapsing-remitting multiple sclerosis, with trial data showing treatment with Tysabri resulting in a 68 per cent relative reduction in the annualised relapse rate compared to placebo.

“There have been no cases of progressive multifocal leukoencephalopathy since re-launch in the US and launch internationally in July 2006,” the company said.

It added that, cumulatively, up to 30,900 patients have been treated with Tysabri, with 6,300 of these receiving the drug for at least one year.

In July 2007, Elan announced that the National Institute for Clinical Health and Excellence had recommended the use of Tysabri in patients with highly-active relapsing-remitting multiple sclerosis.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.